[
    "amount is effective to treat a respiratory disorder or a gastrointestinal disorder. </p>[0318] In another embodiment of the pharmaceutical composition, said gastrointestinal disorder is diarrhea. </p>[0319] In another embodiment of the pharmaceutical composition, said respiratory disorder is asthma, allergic rhinitis, or chronic obstructive pulmonary disease. </p>[0320] In another embodiment of the pharmaceutical composition, said pharmaceutical composition is an ophthalmic formulation. </p>[0321] In another embodiment of the pharmaceutical composition, said pharmaceutical composition is an periocular, retrobulbar or intraocular injection formulation. </p>[0322] In another embodiment of the pharmaceutical composition, said pharmaceutical composition is a systemic formulation. </p>[0323] In another embodiment of the pharmaceutical composition, said pharmaceutical composition is a surgical irrigating solution. </p>[0324] This invention also provides a packaged pharmaceutical composition for treating a disease associated with A<sub>3 </sub>adenosine receptor in a subject, comprising: (a) a container holding a therapeutically effective amount of any of the compounds IV, V, VI, VII, or VIII; and (b) instructions for using said compound for treating said disease in a subject. </p>[0325] Compounds represented by the formula IV, V, VI, VII, and VIII can be synthesized by the Schemes I-IX. </p>[0326] As used herein, \u201cA compound is A<sub>3 </sub>selective.\u201d means that a compound has a binding constant to adenosine A3 receptor of at least ten time higher then that to adenosine A<sub>1</sub>, A<sub>2a</sub>, or A<sub>2b</sub>. </p>[0327] The invention is further illustrated by the following examples which in no way should be construed as being further limiting. The contents of all references, pending patent applications and published patent applications, cited throughout this application, including those referenced in the background section, are hereby incorporated by reference. It should be understood that the models used throughout the examples are accepted models and that the demonstration of efficacy in these models is predictive of efficacy in humans. </p>[0328] A skilled artisan will know that metabolism of the compounds disclosed herein in a subject produces certain biologically active metabolites which can serve as drugs. </p>[0329] This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully in the claims which follow thereafter. </p>EXPERIMENTAL DETAILS [0330] The deazapurines of the invention can be prepared using standard methods for organic synthesis. Deazapurines can be purified by reverse phase HPLC, chromatography, recrystallization, etc. and their structures confirmed by mass spectral analysis, elemental analysis, IR and/or NMR spectroscopy. </p>[0331]",
    "ds in a 96-well microtiter plate. </p>[0613] Adenosine 3 receptor competition radioligand binding: Competition binding on membranes from HEK293 cell stably expressing the human A3 receptor subtype were carried out using agonist [<sup>125</sup>I] AB-MECA as a radioactive ligand. Membranes was diluted in binding buffer [50 mM Tris-HCl, pH 7.4; containing 10 mM MgCl<sub>2</sub>; 1.0 mM EDTA; 0.25% BSA; 2 U/ml adenosine deaminase and 1 protease inhibitor cocktail tablet/50 ml] at concentrations of 0.2 mg/ml. Membranes (10 \u03bcg/well) were incubate with [<sup>125</sup>I] AB-MECA (0.75 nM) in a final volume of 100 \u03bcl of binding buffer at 25\u00b0 C. for 1 hr in the absence and presence of 10 \u03bcM unlabeled IB-MECA or increasing concentrations of competing compounds in a 96-well microtiter plate. </p>[0614] At the end of the incubation, the A<sub>1</sub>, A<sub>2a </sub>and A<sub>3 </sub>receptor subtypes radioligand binding assays was terminated by the addition of ice-cold 50 mM Tris-HCl (pH 7.4) buffer supplemented with 10 mM MgCl<sub>2</sub>, followed by rapid filtration over glass fiber filters (96-well GF/B UniFilters, Packard) previously presoaked in 0.5% polyethylenimine in a Filtermate 196 cell harvester (Packard). The filter plates were dried coated with 50 \u03bcl/well scintillation fluid (MicroScint-20, Packard) and counted in a TopCount (Packard). Assays were performed in triplicate. Non-specific binding was 5.6\u00b10.5%, 10.8\u00b11.4% and 15.1\u00b12.6% of the total binding in a A1R, A2aR and A3R binding assay, respectively. </p>[0615] Adenosine 2b receptor subtype competition radioligand binding: Competition binding on membranes from HEK293 cell stably expressing the human A2b receptor subtype were carried out using A<sub>1 </sub>receptor antagonist [<sup>3</sup>H] DPCPX as a radioactive ligand. Membranes was diluted in binding buffer [10 mM Hepes-KOH, pH 7.4; containing 1.0 mM EDTA; 0.1 mM Benzamidine and 2 U/ml adenosine deaminase] at concentrations of 0.3 mg/ml. Membranes (15 \u03bcg/well) were incubate with [<sup>3</sup>H] DPCPX (15 nM) in a final volume of 100 \u03bcl of binding buffer at 25\u00b0 C. for 1 hr in the absence and presence of 10 \u03bcM unlabeled XAC or increasing concentrations of competing compounds in a 96-well microtiter plate. At the end of the incubation, the assay was terminated by the addition of ice-cold 10 mM Hepes-KOH (pH 7.4) buffer followed by rapid filtration over glass fiber filters (96-well GF/C UniFilters, Packard) previously presoaked in 0.5% polyethylenimine in a Filtermate 196 cell harvester (Packard). The filter plates were dried coated with 50 \u03bcl/well scintillation fluid (MicroScint-20, Packard) and counted in a TopCount (Packard). Assays were performed in triplicate. Non-specific binding was 14.3\u00b12.3% of the total binding. </p>[0616] Specific binding of [<sup>3</sup>H] DPCPX; [<sup>3</sup>H] CGS-21680 and [<sup>125</sup>I] AB-MECA was defined as the difference between the total binding and non-specific binding. Percent inhibition of the compound",
    "; CGS-15943; Compound 600; Compound 1002; NECA, (R)-PIA; IB-MECA and Alloxazine) that competed with [<sup>3</sup>H] DPCPX in the expected rank order. Displacement curves recorded with these compounds show the typical steepness with all the ligands, and the data for each of the ligands could be modeled by a one-site fit. The apparent dissociation constants estimated for the individual compound from the curves (Table 5) are consistent with value published for the receptor obtained from other sources.  \nTABLE 5Ki values for membranes from yeast cells transformed withhuman A<sub>1 </sub>receptor subtypeLigandsK<sub>I </sub>(nM)XAC5.5DPCPX7.1CGS-159410.8NECA179.6(R)-PIA56.3IB-MECA606.5Alloxazine894.1Compound 60013.9Compound 10029.8\n</p>[0619] Tables 6 through 12 demonstrate the efficacy and structure activity profiles of deazapurines of the invention. Tables 13 and 14 demonstrate selectivity can be achieved for human adenosine receptor sites by modulation of the functionality about the deazapurine structure. Table 14 also demonstrates the surprising discovery that the compounds set forth therein have subnanomolar activity and higher selectivity for the A<sub>2b </sub>receptor as compared to the compounds in Table 13.  \nTABLE 6Effect of N<sub>6</sub>-Substituent <img id=\"EMI-C00124\" path=\"US20020094974A1-20020718-C00124.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664241/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00124.TIF\"/>A1BindingYeastCompoundRKi (nM)IC50 (nM)600<img id=\"EMI-C00125\" path=\"US20020094974A1-20020718-C00125.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664476/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00125.TIF\"/>13.997.2 601<img id=\"EMI-C00126\" path=\"US20020094974A1-20020718-C00126.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664251/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00126.TIF\"/>1423&gt;10.000 602<img id=\"EMI-C00127\" path=\"US20020094974A1-20020718-C00127.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664107/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00127.TIF\"/>483.5&gt;10.000 603<img id=\"EMI-C00128\" path=\"US20020094974A1-20020718-C00128.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664485/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00128.TIF\"/>196.64442.0 604<img id=\"EMI-C00129\" path=\"US20020094974A1-20020718-C00129.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664349/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00129.TIF\"/>&gt;10.000&gt;10000 605<img id=\"EMI-C00130\" path=\"US20020094974A1-20020718-C00130.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663941/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00130.TIF\"/>&gt;10000&gt;10000 606<img id=\"EMI-C00131\" path=\"US20020094974A1-20020718-C00131.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664444/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00131.TIF\"/>297.9&gt;10000 607<img id=\"E",
    "11<img id=\"EMI-C00136\" path=\"US20020094974A1-20020718-C00136.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664494/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00136.TIF\"/>785.6&gt;10000 612<img id=\"EMI-C00137\" path=\"US20020094974A1-20020718-C00137.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664246/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00137.TIF\"/>64.8 613<img id=\"EMI-C00138\" path=\"US20020094974A1-20020718-C00138.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664188/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00138.TIF\"/>6726.0 614<img id=\"EMI-C00139\" path=\"US20020094974A1-20020718-C00139.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663975/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00139.TIF\"/>32.1 615<img id=\"EMI-C00140\" path=\"US20020094974A1-20020718-C00140.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664159/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00140.TIF\"/>816.92577.0 616<img id=\"EMI-C00141\" path=\"US20020094974A1-20020718-C00141.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664469/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00141.TIF\"/>34.3\n</p>[0620]TABLE 7Effect of C<sub>2</sub>-Substituent <img id=\"EMI-C00142\" path=\"US20020094974A1-20020718-C00142.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663985/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00142.TIF\"/>A1BindingYeastCompoundRKi (nM)IC50 (nM)700<img id=\"EMI-C00143\" path=\"US20020094974A1-20020718-C00143.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664445/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00143.TIF\"/>604.5&gt;10000 701<img id=\"EMI-C00144\" path=\"US20020094974A1-20020718-C00144.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664386/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00144.TIF\"/>157.7763.1 702<img id=\"EMI-C00145\" path=\"US20020094974A1-20020718-C00145.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663938/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00145.TIF\"/>198.52782.5 703<img id=\"EMI-C00146\" path=\"US20020094974A1-20020718-C00146.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663982/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00146.TIF\"/>443.6&gt;10000 704<img id=\"EMI-C00147\" path=\"US20020094974A1-20020718-C00147.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664127/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00147.TIF\"/>61.1297.0 705<img id=\"EMI-C00148\" path=\"US20020094974A1-20020718-C00148.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664115/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00148.TIF\"/>30.1194.7 706<img id=\"EMI-C00149\" path=\"US20020094974A1-20020718-C00149.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664265/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00149.TIF\"/>19.9 707<img id=\"EMI-C00150\" path=\"US20020094974A1-20020718-C00150.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664443/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00150.TIF\"/>62.8 708<img id=\"EMI-C00151\" path=\"US20020094974A1-20020718-C00151.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664448/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00151.TIF\"/>2145 709<img id=\"EMI-C00152\" path=\"US20020094974A1-20020718-C00152.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664010/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00152.TIF\"/>48.7</p>[0621]TABLE 8Effect of Pyrrole Ring Substituent <img id=\"EMI-C00153\" path=\"US20020094974A1-20020718-C00153.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664414/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00153.TIF\"/>A1YeastBindingIC50CompoundRR\u2032R\u2033R\u2032\u2033Ki (nM)(nM)800<img id=\"EMI-C00154\" path=\"US20020094974A1-20020718-C00154.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664455/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00154.TIF\"/>MeMeMe3311&gt;10000 801<img id=\"EMI-C00155\" path=\"US20020094974A1-20020718-C00155.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664166/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00155.TIF\"/>HMeH22.3148.3 802<img id=\"EMI-C00156\" path=\"US20020094974A1-20020718-C00156.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664460/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00156.TIF\"/>HHMe8.9 803<img id=\"EMI-C00157\" path=\"US20020094974A1-20020718-C00157.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664347/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00157.TIF\"/><img id=\"EMI-C00158\" path=\"US20020094974A1-20020718-C00158.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663964/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00158.TIF\"/>MeMe2210&gt;10000 804<img id=\"EMI-C00159\" path=\"US20020094974A1-20020718-C00159.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664200/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00159.TIF\"/><img id=\"EMI-C00160\" path=\"US20020094974A1-20020718-C00160.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664335/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00160.TIF\"/>MeMe863.1 805<img id=\"EMI-C00161\" path=\"US20020094974A1-2002071",
    "020094974A1-20020718-C00166.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664341/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00166.TIF\"/>MeMe35.3</p>[0622]TABLE 9<img id=\"EMI-C00167\" path=\"US20020094974A1-20020718-C00167.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664022/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00167.TIF\"/> A1YeastBindingIC50CompoundRKi (nM)(nM)900<img id=\"EMI-C00168\" path=\"US20020094974A1-20020718-C00168.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664378/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00168.TIF\"/>863.1 901<img id=\"EMI-C00169\" path=\"US20020094974A1-20020718-C00169.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664192/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00169.TIF\"/>4512 902<img id=\"EMI-C00170\" path=\"US20020094974A1-20020718-C00170.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664437/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00170.TIF\"/>8451 903<img id=\"EMI-C00171\" path=\"US20020094974A1-20020718-C00171.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664440/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00171.TIF\"/>35.3</p>[0623]TABLE 10Effect of N<sub>6</sub>-Substituent <img id=\"EMI-C00172\" path=\"US20020094974A1-20020718-C00172.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664169/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00172.TIF\"/>A1BindingYeastCompoundRKi (nM)IC50 (nM)1000<img id=\"EMI-C00173\" path=\"US20020094974A1-20020718-C00173.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664205/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00173.TIF\"/>1789&gt;10000 1001<img id=\"EMI-C00174\" path=\"US20020094974A1-20020718-C00174.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663928/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00174.TIF\"/>54.41865 1002<img id=\"EMI-C00175\" path=\"US20020094974A1-20020718-C00175.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664384/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00175.TIF\"/>9.882.8 1003<img id=\"EMI-C00176\" path=\"US20020094974A1-20020718-C00176.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664300/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00176.TIF\"/>26.7195.7 1004<img id=\"EMI-C00177\" path=\"US20020094974A1-20020718-C00177.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664387/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00177.TIF\"/>32.8545.8 1005<img id=\"EMI-C00178\" path=\"US20020094974A1-20020718-C00178.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664421/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00178.TIF\"/>147.53972 1006<img id=\"EMI-C00179\" path=\"US20020094974A1-20020718-C00179.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664078/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00179.TIF\"/>151.72918 1007<img id=\"EMI-C00180\" path=\"US20020094",
    "094974A1-20020718-C00183.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664435/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00183.TIF\"/>674.99376.0 1011<img id=\"EMI-C00184\" path=\"US20020094974A1-20020718-C00184.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664101/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00184.TIF\"/>121.92067.5 1012<img id=\"EMI-C00185\" path=\"US20020094974A1-20020718-C00185.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664451/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00185.TIF\"/>233.93462 1013<img id=\"EMI-C00186\" path=\"US20020094974A1-20020718-C00186.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664449/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00186.TIF\"/>270.13009.5 1014<img id=\"EMI-C00187\" path=\"US20020094974A1-20020718-C00187.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664419/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00187.TIF\"/>384.92005 1015<img id=\"EMI-C00188\" path=\"US20020094974A1-20020718-C00188.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664466/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00188.TIF\"/>179.33712 1016<img id=\"EMI-C00189\" path=\"US20020094974A1-20020718-C00189.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664195/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00189.TIF\"/>176.15054</p>[0624]TABLE 11Effect of N<sub>6</sub>-Substituent A1BindingYeastCompoundRKi (nM)IC50 (nM)1100<img id=\"EMI-C00190\" path=\"US20020094974A1-20020718-C00190.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664396/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00190.TIF\"/>9.8115.4 1101<img id=\"EMI-C00191\" path=\"US20020094974A1-20020718-C00191.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664483/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00191.TIF\"/>53.9551.0 1102<img id=\"EMI-C00192\" path=\"US20020094974A1-20020718-C00192.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664432/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00192.TIF\"/>10.3101.3 1103<img id=\"EMI-C00193\" path=\"US20020094974A1-20020718-C00193.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664321/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00193.TIF\"/>71.13217 1104<img id=\"EMI-C00194\" path=\"US20020094974A1-20020718-C00194.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664149/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00194.TIF\"/>6.558.7 1105<img id=\"EMI-C00195\" path=\"US20020094974A1-20020718-C00195.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664105/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00195.TIF\"/>105.4472.1 1106<img id=\"EMI-C00196\" path=\"US20020094974A1-20020718-C00196.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663984/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00196.TIF\"/>27.8162.4 1107<img id=\"EMI-C00197\" path=\"US20020094974A1-20020718-C00197.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664395/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00197.TIF\"/>126.51297.0 1108<img id=\"EMI-C00198\" path=\"US20020094974A1-20020718-C00198.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664137/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00198.TIF\"/>2.3 1109<img id=\"EMI-C00199\" path=\"US20020094974A1-20020718-C00199.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663977/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00199.TIF\"/>9.0 1110<img id=\"EMI-C00200\" path=\"US20020094974A1-20020718-C00200.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663958/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00200.TIF\"/>17.3 1111<img id=\"EMI-C00201\" path=\"US20020094974A1-20020718-C00201.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664087/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00201.TIF\"/>2.5 1112<img id=\"EMI-C00202\" path=\"US20020094974A1-20020718-C00202.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664301/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00202.TIF\"/>213</p>[0625]TABLE 12\u201cRetro-Amide\u201d Analogues <img id=\"EMI-C00203\" path=\"US20020094974A1-20020718-C00203.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663959/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00203.TIF\"/>A1Com-BindingYeastpoundRKi (nM)IC50 (nM)1200<img id=\"EMI-C00204\" path=\"US20020094974A1-20020718-C00204.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664461/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00204.TIF\"/>16.5189.4 1201<img id=\"EMI-C00205\" path=\"US20020094974A1-20020718-C00205.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664457/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00205.TIF\"/>7.445.7 1202<img id=\"EMI-C00206\" path=\"US20020094974A1-20020718-C00206.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664206/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00206.TIF\"/>95.83345.0 1203<img id=\"EMI-C00207\" path=\"US20020094974A1-20020718-C00207.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664283/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00207.TIF\"/>529.14040.0 1204<img id=\"EMI-C00208\" path=\"US20020094974A1-20020718-C00208.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664329/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00208.TIF\"/>1060.0&gt;10000 1205<img id=\"EMI-C00209\" path=\"US20020094974A1-20020718-C00209.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664473/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00209.TIF\"/>1272&gt;10000 1206<img id=\"EMI-C00210\" path=\"US20020094974A1-20020718-C00210.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664029/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00210.TIF\"/>50.84028 1207<img id=\"EMI-C00211\" path=\"US20020094974A1-20020718-C00211.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664319/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00211.TIF\"/>48.5701.5</p>[0626]TABLE 13Profile of Selective Adenosine Antagonists<img id=\"EMI-C00212\" path=\"US20020094974A1-20020718-C00212.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664145/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00212.TIF\"/>Binding Ki (nM)CompoundRA1A2aA2bA31300<img id=\"EMI-C00213\" path=\"US20020094974A1-20020718-C00213.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664462/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00213.TIF\"/>9.8 \u2212 25.118.0 \u2212 48.680.3513.0 1301<img id=\"EMI-C00214\" path=\"US20020094974A1-20020718-C00214.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664211/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00214.TIF\"/>27.850.784.6429.8 1302<img id=\"EMI-C00215\" path=\"US20020094974A1-20020718-C00215.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664385/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00215.TIF\"/>20.275.620.14.3 1303<img id=\"EMI-C00216\" path=\"US20020094974A1-20020718-C00216.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664217/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00216.TIF\"/>17.4111.3120.644.6 1304<img id=\"EMI-C00217\" path=\"US20020094974A1-20020718-C00217.TIF\" file=\"https://surechembl.org/api/assets/attachment/18663949/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00217.TIF\"/>13.9 \u2212 30.9933.7138.021.5 1305<sup>1</sup><img id=\"EMI-C00218\" path=\"US20020094974A1-20020718-C00218.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664116/US/20020718/A1/020020/09/49/74/US20020094974A1-20020718-C00218.TIF\"/>46.6730.930%9.9 1306<sup>2</sup><img id=\"EMI-C00219\" path=\"US20020094974A1-20020718-C00219.TIF\" file=\"https://surechembl.org/api/assets/attachment/18664463/US/20020718/A1"
]